nifuratel 200 mg;
polyethylene glycol 6000;
Macmiror - antimicrobial, antiprotozoal, antifungal.
Nifuratel, an antimicrobial agent from the group of nitrofurans; has antiprotozoal, antifungal and antibacterial effects.
Nifuratel possesses high efficiency and low toxicity, which leads to a wide range of its clinical applications.
It is highly effective against Papiliobacter and Helicobacter pylori, gram-positive and gram-negative microorganisms: at a minimum inhibitory concentration (MIC) of 12.5–25 μg / ml, it inhibits 44.3 to 93.2% of cultures.
Shows high activity against both aerobic and anaerobic pathogens.
Spectrum of action includes: Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Shigella flexneri 2a, Shigella flexneri 6, Shigella sonnei, Salmonella typhi, Sermonella typhimurium, Salmonella spp. , Citrobacter spp., Morganella spp., Rettgerella spp., Pragia fontium, Budvicia aquatica, Rachnella aquatilis and Acinetobacter spp., Other atypical enterobacteria, as well as protozoa (amoeba, giardia); less active against Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa.
It is the drug of choice for the treatment of salmonellosis, shigellosis and other intestinal bacterial infections.
Active against Trichomonas vaginalis, highly active against fungi of the genus Candida.
It is especially effective against metronidazole-resistant strains of Helicobacter pylori.
The obtained data indicate the high activity of nifuratel (in vitro and in vivo) against Atopobium vaginae, the main marker of bacterial vaginosis.
When taken orally, it is rapidly absorbed from the gastrointestinal tract. Penetrates the BBB and the hematoplacental barrier, excreted in breast milk. Metabolized in the liver and muscle tissue. It is completely eliminated from the body by the kidneys (30-50% - unchanged), providing a strong antibacterial effect in the urinary tract.
- vulvovaginal infections caused by pathogens sensitive to the drug (pathogenic microorganisms, candida, Trichomonas, bacteria, chlamydia);
- chronic inflammatory diseases of the upper gastrointestinal tract associated with Helicobacter pylori (chronic gastritis, gastric ulcer and duodenal ulcer, gastroesophageal reflux disease);
- intestinal amebiasis and giardiasis;
- pyelonephritis, urethritis, cystitis, pyelitis and other diseases of the urinary system.
Hypersensitivity to the active substance or any component of the drug.
Dyspeptic disorders: nausea, vomiting, bitterness in the mouth, diarrhea, heartburn, gastralgia.
Allergic reactions: skin rash, itching.
Enhances the antifungal effect of nystatin.
How to take, course of administration and dosage
The drug is taken orally, following the recommendations.
For vaginal infections: adults - 1 tablet 3 times a day after meals for 7 days (both sexual partners must take the drug); the recommended dose for children is 10 mg / kg of body weight 2 times a day for 10 days.
Gastrointestinal tract infections associated with Helicobacter pylori: adults - 2 tablets 2 times a day for 7 days; the recommended dose for children is 15 mg / kg of body weight 2 times a day for 7 days. The duration of the course may vary depending on the chosen eradication scheme.
In case of intestinal amebiasis: for adults - 2 tablets 2-3 times a day for 10 days; children - 10 mg / kg of body weight 3 times a day. The course of treatment is 7-10 days.
With giardiasis: adults - 2 tables. 2-3 times a day for 7 days; children - 15 mg / kg of body weight 2 times a day for 7 days.
In case of urinary tract infections: for adults, depending on the severity of the course of the disease, 3–6 tablets daily for 7–14 days; the recommended dose for children is 15-30 mg / kg of body weight 2 times a day for 7-14 days. Treatment of urinary tract infections may be extended or repeated on the recommendation of a doctor.
When monotherapy of vaginal infections with Macmiror, it is recommended to increase the daily dosage to 4-6 tablets. During the period of treatment, one should refrain from sexual intercourse.
Impact on the ability to drive a car or other mechanisms: no negative effect has been identified.